Pharmaceutical Product Development (PPDI) Reports Inline Q3 EPS of $0.32
PPDI Hot Sheet
Financial Fact:(Loss ) income from equity method investment: 1.92M
Today's EPS Names:
TARO, BRLI, TLB, More
Pharmaceutical Product Development (NASDAQ: PPDI) reports Q3 EPS of $0.32, inline with the analyst estimate of $0.32. Revenue for the quarter was $341.1 million, which compares to the estimate of $334.16 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
- Infoblox (BLOX) Tops Q3 EPS by 4c; Guides Q4
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
